A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: Review of immunogenicity and safety

Vaccine

Volumn 22, Issue 11-12, 2004, Pages 1343-1357

  Mallet, Eric ^a   Belohradsky, Bernd H ^b   Lagos, Rosanna ^c   Gothefors, Leif ^d   Camier, Patrice ^e   Carrière, Jean Pierre ^f   Kanra, Güler ^g   Hoffenbach, Agnès ^h   Langue, Jacques ^e   Undreiner, François ^e   Roussel, François ^e   Reinert, Philippe ⁱ   Flodmark, Carl Erik ^j   Stojanov, Silvia ^b   Liese, Johannes ^b   Levine, Myron M ^k   Muñoz, Alma ^c   Schödel, Florian ^l   Hessel, Luc ^h  

^a HÔPITAL CHARLES NICOLLE   (France)

^b UNIVERSITY OF MUNICH   (Germany)

^c Centro para Vacunas en Desarrollo Chile   (Chile)

^d University Hospital   (United States)

^e Assoc Francaise Chir Ambulatoire   (France)

^f CHU PURPAN   (France)

^g HACETTEPE UNIVERSITY   (Turkey)

^h SANOFI PASTEUR   (France)

ⁱ School of Medicine ^*

^j University Hospital   (United States)

^k UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^l MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

Combination vaccine; Hepatitis B; Hib; Paediatric immunization

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; PENTAVAC;

CLINICAL TRIAL; DIPHTHERIA; DROWSINESS; DRUG SAFETY; EDEMA; ERYTHEMA; FEVER; HEPATITIS B; HUMAN; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INFLUENZA; IRRITABILITY; PERTUSSIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; SIDE EFFECT; SKIN MANIFESTATION; TETANUS; VACCINATION;

EID: 11144357611     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.09.039     Document Type: Review

References (66)

1. American Academy of Pediatrics. Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). Pediatrics 1999;103:1064-77.
2. Rümke H.C. Are different combined vaccines needed in different parts of Europe? A point of view from a Northern European country. Biologicals. 22:1994;425-427.
3. Eskola J. Epidemiological views into possible components of paediatric combined vaccines in 2015. Biologicals. 22:1994;323.
4. Decker M.D., Edwards K.M. Acellular pertussis vaccines. Pediatr. Clin. North. Am. 47:2000;309-335.
5. Decker M.D., Edwards K.M., Steinhoff M.C.et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics. 96(Suppl.):1995;557-566.
6. Edwards K.M., Meade B.D., Decker M.D.et al. Comparison of 13 acellular pertussis vaccines: overview and serological response. Pediatrics. 96(Suppl.):1995;548-557.
7. Cherry J.D. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr. Infect. Dis. J. 16:1997;S90-S96.
8. Liese J.G., Meschievitz C.K., Harzer E.et al. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr. Infect. Dis. J. 16:1997;1038-1044.
9. Plotkin S.A., Cadoz M. The acellular pertussis vaccine trials: an interpretation. Pediatr. Infect. Dis. J. 16:1997;508-517.
10. Plotkin S.A. Inactivated poliomyelitis vaccine for the United States: a missed vaccination opportunity. Pediatr. Infect. Dis. J. 14:1995;835-839.
11. Peltola H. Haemophilus influenzae type b disease and vaccination in Europe: lessons learned. Pediatr. Infect. Dis. J. 17(Suppl.):1998;S126-S132.
12. Shapiro C.N. Epidemiology of hepatitis B. Pediatr. Infect. Dis. J. 12:1993;433-437.
13. WHO and Viral Hepatitis Prevention Board. Prevention and control of hepatitis B in the community. Communicable diseases series no. 1; 1996.
14. Kanra G., Silier T., Yurdakök K.et al. Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTaP-IPV//PRP-T) administered simultaneously with a hepatitis B vaccine at two, three and four months of life. Vaccine. 18:2000;947-954.
15. The European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products. Points to consider on the reduction, elimination or substitution of thiomersal in vaccines. CPMP/BWP/2517/00, London: EMEA; 26 April 2001.
16. Mallet E., Fabre P., Pines E.et al. Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants. Pediatr. Infect. Dis. J. 19:2000;1119-1127.
17. Lagos R, Muñoz A, Fabre P, et al. Safety and immunogenicity of 3 consistency lots of a liquid hexavalent vaccine given at 2, 4 and 6 months of age. In: Proceedings of the 37th Annual Meeting of the Infectious Diseases Society of America. Philadelphia USA, 18-21 November 1999 [abstract].
18. Camier P, Langue J, Undreiner F, et al. Immunogenicity and safety of a liquid hexavalent combined vaccine administered to healthy infants at 2, 3, 4 or 2, 4, 6 months and at 15-17 months. Nordwijk. In: Proceedings of the European Society for Paediatric Infectious Diseases. The Netherlands, 3-5 May 2000 [abstract].
19. Lagos R., Kotloff K., Hoffenbach A.et al. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants. Pediatr. Infect. Dis. J. 17:1998;294-304.
20. Carlsson R.-M., Claesson B.A., Selstam U.et al. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr. Infect. Dis. J. 17:1998;1026-1033.
21. Pichichero M.E., Latiolais T., Bernstein D.I.et al. Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, four- and six-month-old infants. Pediatr. Infect. Dis. J. 16:1997;863-870.
22. ® vaccines in French infants. In: Proceedings of the Abstracts of the 37th IDSA Annual Meeting; Clin Infect Dis 1999;29:abstract 642.
23. Silier T, Langue J, Blondeau C, Fritzell B. Simultaneous administration of DTaP-IPV-Act-HIB and MMR vaccines at 14 to 16 months. In: Proceedings of the European Society for Paediatric Infectious Disease. Helsingør, Denmark, 18-21 June 1996 [abstract 22].
24. Liese J.G., Stojanov S., Berut F.et al. Large scale safety study of a liquid hexavalent vaccine (D-T-acP-IPV-PRPT-HBs) given at 2, 4, 6 and 12 to 14 months of age. Vaccine. 20:2002;448-454.
25. Carrière JP, Giard P, Muller JM, et al. Safety and reactogenicity of a liquid hexavalent combined vaccine administered to healthy toddlers aged 16-20 months. In: Proceedings of the European Society for Paediatric Infectious Diseases. Nordwijk, The Netherlands, 3-5 May 2000 [abstract].
26. Hoppenbrouwers K., Kanra G., Roelants M.et al. Priming effect, immunogenicity and safety of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey. Vaccine. 17:1999;875-886.
27. Hoppenbrouwers K., Lagos R., Swennen B.et al. Safety and immunogenicity of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DTP) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile. Vaccine. 16:1998;921-927.
28. Liese JG, Harzer E, Hosbach P, Froeschle J, Meschiewitz CK, Belohradsky BH. Hib antibody response of a combined DTaP-PRP-T conjugate vaccine compared to separate injections in infants. In: Proceedings of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA, 15-18 September 1996. Washington, DC: American Society for Microbiology; 1996. p. 162 [abstract G-105].
29. Eskola J., Ölander R.M., Hovi T., Litmanen L., Peltola H., Käyhty H. Randomized trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet. 348:1996;1688-1692.
30. Dagan R, Agbaria K, Piglansky L, Melamed R, Willems P, Grossi A. Immunogenicity of a combined diphtheria, tetanus, acellular pertussis, inactivated poliovirus and H. influenzae type b conjugate vaccine (DTPa-IPV-Hib) in infants. In: Proceedings of the 36th International Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA, 15-18 September 1996. Washington, DC: American Society for Microbiology; 1996. p. 154 [abstract G-59].
31. Robbins J.B., Schneerson R. Evaluating the Haemophilus influenzae type b conjugate vaccine PRP-D. N. Engl. J. Med. 323:1990;1415-1416.
32. Eskola J., Ward J., Dagan R., Goldblatt D., Zepp F., Siegrist C.-A. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis-containing acellular pertussis. Lancet. 354:1999;2063-2068.
33. Eskola J., Käyhty H., Takala A.K.et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N. Engl. J. Med. 323:1990;1381-1387.
34. 197 protein vaccines in infancy. Arch. Pediatr. Adolesc. Med. 148:1994;620-625.
35. Santosham M., Wolff M., Reid R.et al. The efficacy in Navajo Indians of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis-outer-membrane protein complex. N. Engl. J. Med. 324:1991;1767-1772.
36. Goldblatt D., Pinto Vaz A.R., Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J. Infect. Dis. 177:1998;1112-1115.
37. Booy R., Heath P.T., Slack M.P.E., Begg N., Moxon E.R. Vaccine failures after primary immunisation with Haemophilus influenzae type b conjugate vaccine without booster. Lancet. 349:1997;1197-1202.
38. Goldblatt D., Miller E., McCloskey N., Cartwright K. Immunological response to conjugate vaccines in infants: follow-up study. Br. Med. J. 316:1998;1570-1571.
39. Black S.B., Shinefield H.R., Fireman B., Hiatt R., Polen M., Vittinghoff E. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61080 children. Pediatr. Infect. Dis. J. 10:1991;97-104.
40. Käyhty H., Peltola H., Karanko V., Mäkelä P.H. The protective level of antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J. Infect. Dis. 147:1983;1100.
41. Schmitt H.J., Zepp F., Müschenborn S.et al. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus toxoid and acellular pertussis vaccine for primary and booster immunizations. Eur. J. Pediatr. 157:1998;208-214.
42. Bell F., Heath P., Shackley F.et al. Effect of combination with an acellular pertussis, diphtheria, tetanus vaccine on antibody response to Hib vaccine (PRP-T). Vaccine. 16:1998;637-642.
43. Kähyty H., Eskola J., Peltola H., Saarinen L., Mäkelä P.H. High antibody responses to booster doses of either Haemophilus influenzae type b capsular polysaccharide or conjugate vaccines after primary immunization with conjugate vaccine. J. Infect. Dis. 147:1992;1100.
44. Zepp F., Schmitt H.J., Kaufhold A.et al. Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b-PRP (Hib) boosters in children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine. Eur. J. Pediatr. 156:1997;18-24.
45. Schmitt H.-J., von Kries R., Hassenpflug B.et al. Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influenzae type b combination vaccines. Pediatr. Infect. Dis. J. 20:2001;767-774.
46. Szmuness W., Stevens C.E., Zang E.A., Harley E.J., Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1:1981;377-385.
47. Francis D.P., Hadler S.C., Thompson S.E.et al. The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann. Int. Med. 97:1982;362-366.
48. Coutinho R.A., Lelie N., Albrecht-Van Lent P.et al. Efficacy of a heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial. Br. Med. J. 286:1983;1305-1308.
49. Kanra G., Ceyhan M., Ecevit Z.et al. Primary vaccination of infants with a combined diphtheria-tetanus-acellular pertussis-hepatitis B vaccine. Pediatr. Infect. Dis. J. 14:1995;998-1000.
50. Pichichero M.E., Passador S. Administration of combined diphtheria and tetanus toxoids and pertussis vaccine, hepatitis B vaccine, and Haemophilus influenzae type b (Hib) vaccine to infants and response to a booster dose of Hib conjugate vaccine. Clin. Infect. Dis. 25:1997;1378-1384.
51. West D.J., Hesley T.M., Jonas L.C.et al. Safety and immunogenicity of a bivalent Haemophilus influenzae type b/hepatitis B vaccine in healthy infants. Pediatr. Infect. Dis. J. 16:1997;593-599.
52. Greenberg D., Vadheim C.M., Marcy M.et al. Safety and immunogenicity of a recombinant hepatitis B vaccine administered to infants at 2, 4 and 6 months of age. Vaccine. 14:1996;811-816.
53. Keyserling H.L., West D.J., Hesley T.M., Bosley C., Wiens B.L., Calandra G.B. Antibody responses of healthy infants to a recombinant hepatitis B vaccine administered at two, four and twelve or fifteen months of age. J. Pediatr. 125:1994;67-69.
54. Banatvala J., Van Damme P., Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine. 19:2001;877-885.
55. Da Villa G., Pellicia M.G., Peluso F., Ricciardi E., Sepe A. Anti-HBs responses in children vaccinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine. Res. Virol. 148:1997;109-114.
56. Resti M., Di Francesco G., Azzari C., Rossi M.E., Vierucci A. Anti-HBs and immunological memory to HBV vaccine: implication for booster timing. Vaccine. 11:1993;1079.
57. Marsano L.S., West D.J., Chan I.et al. A two-dose hepatitis B vaccine regimen: proof of priming and memory responses in young adults. Vaccine. 16:1998;624-629.
58. Moyes C.D., Milne A., Waldon J. Very low dose hepatitis B vaccination in the newborn: anamnestic response to booster at four years. J. Med. Virol. 30:1990;216-218.
59. Wainwright R.B., Bulkow L.R., Parkinson A.J., Zanis C., McMahon B.J. Protection provided by hepatitis B vaccine in a Yupik Eskimo population. Results of a 10-year study. J. Infect. Dis. 175:1997;674-677.
60. Jack A.D., Hall A.J., Maine N.et al. What level of hepatitis B antibody is protective? J. Infect. Dis. 179:1999;489-492.
61. Poland G.A. Acellular pertussis vaccines: new vaccines for an old disease. Lancet. 347:1996;209-210.
62. Trollfors B., Taranger J., Lagergard T.et al. A placebo-controlled trial of a pertussis toxoid vaccine. N. Engl. J. Med. 333:1995;1045-1050.
63. Storsaeter J., Hallander H., Farrington C.P.et al. Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine. 8:1990;457-461.
64. Storsaeter J., Olin P. Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance. Vaccine. 10:1992;142-144.
65. He Q., Viljanen M.K., Ölander R.-M.et al. Antibodies to filamentous hemagglutinin of Bordetella pertussis and protection against whooping cough in schoolchildren. J. Infect. Dis. 170:1994;705-708.
66. Simondon F., Preziosi M.-P., Yam A.et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine. 15:1997;1606-1612.